BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16604529)

  • 1. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
    Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
    Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
    Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
    Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules.
    Zell JA; Ou SH; Ziogas A; Anton-Culver H
    Cancer; 2008 Jan; 112(1):136-43. PubMed ID: 17960795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
    Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
    Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage IB nonsmall cell lung cancers: are they all the same?
    Jones DR; Daniel TM; Denlinger CE; Rundall BK; Smolkin ME; Wick MR
    Ann Thorac Surg; 2006 Jun; 81(6):1958-62; discussion 1962. PubMed ID: 16731113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
    Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
    J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
    Tsao AS; Liu D; Lee JJ; Spitz M; Hong WK
    Cancer; 2006 Jun; 106(11):2428-36. PubMed ID: 16634096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
    Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
    Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy.
    Germain F; Wai ES; Berthelet E; Truong PT; Lesperance M
    Am J Clin Oncol; 2008 Dec; 31(6):561-6. PubMed ID: 19060588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
    Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
    Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.